Literature DB >> 8136722

Differential effect of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell-parasite interaction.

S L de-Castro1, M N Soeiro, K O Higashi, M N Meirelles.   

Abstract

1. Amphotericin B (Am.B) was shown to have a direct effect on T. cruzi, with the three forms of the parasite presenting different susceptibilities to the drug in the following order: amastigotes > trypomastigotes > epimastigotes. These differences highlight the importance of using the vertebrate forms of the parasite in tests of new drugs. 2. The treated parasites showed alterations of the plasma membrane, suggesting that, as in fungi, the primary effect of Am.B was probably via formation of complexes with membrane components. 3. When exposed to filipin, another polyene antibiotic, the three parasite forms were observed to present a similar order of susceptibility, with comparable ultrastructural modifications. 4. Higher concentrations of Am.B were required to damage the intracellular parasites in vitro, 2.3 micrograms/ml for parasites inside peritoneal macrophages and 7 micrograms/ml for parasites inside heart muscle cells. 5. Am.B is effective against the parasite, but is also toxic to mammalian cells. Testing of Am.B for the control of Chagas' disease by blood transfusion may be useful, since bloodstream forms are lysed by lower concentrations of the drug than those required to affect intracellular parasites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136722

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome.

Authors:  Sabrina Cencig; Nicolas Coltel; Carine Truyens; Yves Carlier
Journal:  PLoS Negl Trop Dis       Date:  2011-06-28

4.  Ergosterol isolated from the basidiomycete Pleurotus salmoneostramineus affects Trypanosoma cruzi plasma membrane and mitochondria.

Authors:  Tatiana Rodrigues Alexandre; Marta Lopes Lima; Mariana Kolos Galuppo; Juliana Tonini Mesquita; Matilia Ana do Nascimento; Augusto Leonardo Dos Santos; Patricia Sartorelli; Daniel Carvalho Pimenta; Andre Gustavo Tempone
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-05-30

5.  Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.

Authors:  Caio H Franco; David C Warhurst; Tapan Bhattacharyya; Ho Y A Au; Hai Le; Miriam A Giardini; Bruno S Pascoalino; Ana Claudia Torrecilhas; Lavinia M D Romera; Rafael Pedro Madeira; Sergio Schenkman; Lucio H Freitas-Junior; Eric Chatelain; Michael A Miles; Carolina B Moraes
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2020-06-13       Impact factor: 4.077

Review 6.  Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi.

Authors:  Gustavo Benaim; Alberto E Paniz-Mondolfi; Emilia Mia Sordillo; Nathalia Martinez-Sotillo
Journal:  Front Cell Infect Microbiol       Date:  2020-02-14       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.